Tier 2 — strong

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review

Deepmala, John Slattery, Nihit Kumar, Leanna Delhey, Michael Berk, Olivia Dean, Charles Spielholz, Richard Frye
Neurosci Biobehav Rev 2015 55:294-321

Bibliography

PubMed
PMID 25957927
DOI
10.1016/j.neubiorev.2015.04.015
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignSystematic review of clinical trials across psychiatric and neurologic conditions
ModelHuman
SampleMultiple clinical trials across disorders
InterventionNAC across psychiatric and neurologic indications
DurationVaried
EndpointsCondition-specific psychiatric and neurologic symptom outcomes; Safety and tolerability

What the study showed, in plain terms

2015 evidence record examining NAC in psychiatry and neurology.

Key findings

The review found favorable or promising evidence in several disorders but characterized anxiety and ADHD evidence as preliminary and in need of larger confirmatory studies.

What this study can and cannot tell us

Broad heterogeneous review across many diagnoses, doses and trial designs; older evidence base and not a direct anxiety meta-analysis.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology